MAINPOINTE PHARMACEUTICALS LLC 13D and 13G filings for RepliCel Life Sciences Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-12-21 3:08 pm Purchase | 2021-12-17 | 13D | REPLICEL LIFE SCIENCES INC REPCF | MAINPOINTE PHARMACEUTICALS LLC | 3,986,687 10.340% | 1,479,885 (+59.03%) | Filing |
| 2021-06-03 6:46 pm Purchase | 2021-04-23 | 13D | REPLICEL LIFE SCIENCES INC REPCF | MAINPOINTE PHARMACEUTICALS LLC | 2,506,802 6.770% | 2,506,802 (New Position) | Filing |